Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Whitlock

Showing results (11-20 of 77) with videos related to

Pageof 8
Sort By:
BMJ (Clinical Research Ed.)|December 14, 2002
Evaluating treatment effects reliablyMartin J Landray, Gary Whitlock
The Lancet. HIV|April 1, 2017
Not just PrEP: other reasons for London's HIV declineNneka Nwokolo, Gary Whitlock, Alan McOwan
The Lancet. HIV|April 29, 2021
Towards no missed opportunities: the experience of 56 Dean StreetSam Gregson, Alan McOwan, Gary Whitlock, et al.
The Lancet. HIV|December 23, 2022
Nurse-led PrEP provision at 56 Dean StreetGary Whitlock, Jon Clark, Vicky Tittle, et al.
The New England Journal of Medicine|March 5, 2010
Effects of obesity and smoking on U.S. life expectancyRichard Peto, Gary Whitlock, Prabhat Jha
Cancer Causes & Control : CCC|February 22, 2012
Social inequalities, tobacco chewing, and cancer mortality in south India: a case-control analysis of 2,580 cancer deaths among non-smoking non-drinkersVendhan Gajalakshmi, Gary Whitlock, Richard Peto
Seminars in Vascular Medicine|October 14, 2005
Coronary heart disease and body mass index: a systematic review of the evidence from larger prospective cohort studiesGary Whitlock, Sarah Lewington, Cliona Ni Mhurchu
The Lancet. HIV|February 7, 2020
Antiretroviral resistance and management after pre-exposure to prophylaxisVictoria Tittle, Marta Boffito, Alan McOwan, et al.
Antiviral Therapy|September 3, 2016
Outcomes of acutely HIV-1-infected individuals following rapid antiretroviral therapy initiationNicolò Girometti, Nneka Nwokolo, Alan McOwan, et al.
The New Zealand Medical Journal|November 15, 2003
Discriminative ability of a risk-prediction tool derived from the Framingham Heart Study compared with single risk factorsRichard Milne, Gregory Gamble, Gary Whitlock, et al.
Pageof 8

Showing results (11-20 of 77) with videos related to

Sort By:
Pageof 8
BMJ (Clinical Research Ed.)|December 14, 2002
Evaluating treatment effects reliablyMartin J Landray, Gary Whitlock
The Lancet. HIV|April 1, 2017
Not just PrEP: other reasons for London's HIV declineNneka Nwokolo, Gary Whitlock, Alan McOwan
The Lancet. HIV|April 29, 2021
Towards no missed opportunities: the experience of 56 Dean StreetSam Gregson, Alan McOwan, Gary Whitlock, et al.
The Lancet. HIV|December 23, 2022
Nurse-led PrEP provision at 56 Dean StreetGary Whitlock, Jon Clark, Vicky Tittle, et al.
The New England Journal of Medicine|March 5, 2010
Effects of obesity and smoking on U.S. life expectancyRichard Peto, Gary Whitlock, Prabhat Jha
Cancer Causes & Control : CCC|February 22, 2012
Social inequalities, tobacco chewing, and cancer mortality in south India: a case-control analysis of 2,580 cancer deaths among non-smoking non-drinkersVendhan Gajalakshmi, Gary Whitlock, Richard Peto
Seminars in Vascular Medicine|October 14, 2005
Coronary heart disease and body mass index: a systematic review of the evidence from larger prospective cohort studiesGary Whitlock, Sarah Lewington, Cliona Ni Mhurchu
The Lancet. HIV|February 7, 2020
Antiretroviral resistance and management after pre-exposure to prophylaxisVictoria Tittle, Marta Boffito, Alan McOwan, et al.
Antiviral Therapy|September 3, 2016
Outcomes of acutely HIV-1-infected individuals following rapid antiretroviral therapy initiationNicolò Girometti, Nneka Nwokolo, Alan McOwan, et al.
The New Zealand Medical Journal|November 15, 2003
Discriminative ability of a risk-prediction tool derived from the Framingham Heart Study compared with single risk factorsRichard Milne, Gregory Gamble, Gary Whitlock, et al.
Pageof 8